W
e are entering an era in which minimally invasive surgical procedures are gaining preferability and acceptability. This has been clearly demonstrated for facial aesthetic procedures and is now gaining momentum in breast aesthetics. Fat grafting to the breast, once considered taboo, is now routinely performed in the setting of breast reconstruction and may one day soon be performed routinely for cosmetic breast augmentation. Other materials, such as the one described in this study, are now being tested in search of an alternative or perhaps the ideal filler material. 1 As with all products and devices, however, studies are necessary to determine whether these minimally invasive procedures have safety and efficacy profiles that are equivalent to those of traditional procedures as well as generating outcomes that are predictable and reproducible.
Macrolane (Q-Med AB, Uppsala, Sweden) is a cross-linked stabilized hyaluronic acid-based gel of nonanimal origin that has been used as a biodegradable filler material in humans. In researching this product, I was somewhat surprised to learn that a specific Web site was on the Internet and promoting this product for breast augmentation in 17 countries throughout Europe and Asia (excluding the United States). 2 According to the Macrolane Web site, its use has been described for scar reduction and for the correction of contour deformities following liposuction. It is also being marketed for breast enhancement, buttock augmentation, and calf shaping. Unfortunately, there have not been any controlled clinical trials evaluating its safety and efficacy profile when it comes to breast enhancement surgery. The only article evaluating its role in breast surgery was published by Inami et al. in the Japanese Journal of Plastic and Reconstructive Surgery in 2006. 3 Unfortunately, this article and journal are not accessible via PubMed, and the journal does not have a Web site. Therefore, we really have no idea as to the quality of the study and whether the material used in that study was exactly the same as the material used in this study. It should be noted that Macrolane is not U.S. Food and Drug Administration approved, not available in the United States, and not being studied in clinical trials at the time of this preparation according to the Food and Drug Administration Web site. 4 The present study is an institutional review board-type agency-approved (Karolinska Institute and Medical Product Agency, Stockholm, Sweden), preliminary evaluation evaluating the potential application of Macrolane injection for breast augmentation in 24 women. The Macrolane injections were into the subglandular space or into the dual-plane spaces (subglandular and subpectoral). The injections were approximately 100 cc per breast. Postoperative magnetic resonance imaging scans demonstrated that the Macrolane was injected into the correct space and not into the breast parenchyma. Postoperative outcome analysis demonstrated that the Macrolane was present in 78 percent of breasts at 3 months, 57 percent of breasts at 6 months, and 34 percent of breasts at 12 months. Patient-assessed breast improvement scores were 95 percent at 3 months, 83 percent at 6 months, and 69 percent at 12 months. Physician scores were slightly higher than patient scores. Adverse events were noted in 69 percent of women and included capsular contracture in 25 percent, breast tenderness in 25 percent, visibility in 29 percent, and displacement in 38 percent.
These authors should be congratulated for conducting this well-designed study. It appears some women may derive some benefit from this technique, but the potential shortcomings cannot be ignored. There will be questions regarding its indications, applicability, safety, and efficacy in light of and despite the data presented in this www.PRSJournal.comarticle. Questions regarding breast imaging following this technique are a certainty. Is there diffusion of the material or byproducts of the material from the periparenchymal space into the breast parenchyma? Are there residual changes in the periparenchymal space or the breast itself following full resorption of the Macrolane? Are any of these changes harmful, deleterious, or premalignant? Are there consequences related to the contour of the breast following full resorption? Clearly long-term follow-up is necessary; 2-, 5-, and 10-year outcomes will be useful. Other considerations include patient candidacy for this technique. Are there women in whom this technique is contraindicated or is any woman with micromastia a candidate? What about women with diabetes mellitus or who use tobacco products? Is there a safety profile in these patients? The cost of the material is another consideration. I would be curious to learn the percentage of women who would repeat the procedure. On a positive note, there may be potential use for this product in women with partial breast deformities following lumpectomy and radiation. Unfortunately, the effectiveness of this material in a radiated bed is not known and may, in fact, be contraindicated.
In summary, my feeling on this topic of injectable materials for breast volume enhancement in the cosmetic patient seeking breast augmentation is that we need to proceed with caution. Just like fat grafting, Macrolane for breast augmentation must go through the same process before consideration for everyday use, at least in the United States. These materials should be tested in a controlled, randomized, and prospective fashion to determine their safety and efficacy profile. In an ideal world, it would have been preferred if the primary investigator were not a consultant for the company. This study, however, conducted under the direction of a reputable and highly regarded plastic surgeon, represents the first steps in the right direction.
